…
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -56.80M | -94.19M | -33.94M | -1.23M | -0.91M |
| Net income | -47.26M | -93.04M | -34.10M | -1.23M | -0.91M |
| Selling general administrative | 30.16M | 59.06M | 14.40M | 0.51M | 0.91M |
| Reconciled depreciation | 3.18M | 2.62M | 0.00M | - | - |
| Ebit | -66.33M | -96.36M | -33.77M | -18.39M | - |
| Ebitda | -74.37M | -93.75M | -33.03M | - | - |
| Depreciation and amortization | -8.04M | 2.62M | 0.74M | - | - |
| Non operating income net other | 9.54M | -0.34M | - | - | - |
| Operating income | -66.33M | -96.36M | -33.03M | -1.23M | -0.91M |
| Other operating expenses | 66.33M | 93.85M | 33.03M | - | - |
| Interest expense | 1.50M | 0.36M | 0.16M | 0.00M | 0.00M |
| Tax provision | 0.00M | -1.16M | 0.00M | - | - |
| Interest income | - | - | 0.73M | 0.03M | 0.00M |
| Net interest income | 1.50M | -0.36M | -0.16M | - | - |
| Income tax expense | -9.54M | -1.16M | 0.16M | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | - | - |
| Total operating expenses | 66.33M | 93.85M | 33.03M | - | - |
| Total other income expense net | 9.54M | 2.17M | -0.91M | - | - |
| Net income from continuing ops | -56.80M | -93.04M | -33.94M | - | - |
| Net income applicable to common shares | -56.80M | -93.04M | -33.94M | -18.34M | -0.91M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 124.54M | 169.99M | 164.00M | 81.52M | 11.96M |
| Intangible assets | 0.53M | 3.69M | 6.87M | 4.67M | 5.22M |
| Other current assets | 4.17M | 3.91M | 3.68M | 1.43M | 3.69M |
| Total liab | 46.41M | 19.08M | 12.34M | 5.65M | 1.96M |
| Total stockholder equity | 78.13M | 150.92M | 151.66M | 75.87M | 10.00M |
| Other current liab | 28.11M | 15.71M | 6.23M | 0.99M | - |
| Common stock | - | - | - | 105.60M | 15.32M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Retained earnings | -290.20M | -194.47M | -137.67M | -44.64M | -5.47M |
| Other liab | - | 1.18M | 1.93M | 2.64M | - |
| Good will | 19.92M | 19.92M | 19.92M | 0.00M | - |
| Other assets | 0.00M | 0.33M | - | - | - |
| Cash | 99.70M | 142.14M | 133.54M | 80.09M | - |
| Total current liabilities | 32.25M | 17.89M | 10.41M | 3.01M | 1.96M |
| Net debt | -85.58M | -142.07M | -133.54M | -80.09M | - |
| Short term debt | - | 0.07M | - | - | - |
| Short long term debt total | 14.13M | 0.07M | - | - | - |
| Other stockholder equity | 367.99M | 344.76M | 288.29M | 120.22M | 0.15M |
| Total current assets | 103.87M | 146.06M | 137.22M | 81.52M | 6.74M |
| Net tangible assets | - | 127.31M | 124.88M | 75.87M | 4.78M |
| Long term debt | 14.13M | - | - | - | - |
| Accounts payable | 4.14M | 2.11M | 4.18M | 2.02M | 1.18M |
| Accumulated other comprehensive income | 0.34M | 0.63M | 1.05M | 0.28M | - |
| Retained earnings total equity | - | -194.47M | -137.67M | - | - |
| Non currrent assets other | 0.22M | 0.33M | - | - | - |
| Non current assets total | 20.67M | 23.94M | 26.79M | 0.00M | - |
| Capital lease obligations | - | 0.07M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.00M | -0.30M | 0.00M | - | - |
| Change to liabilities | -2.47M | 5.91M | 0.54M | 2.09M | - |
| Total cashflows from investing activities | - | -0.30M | -0.30M | -0.30M | 0.57M |
| Total cash from financing activities | 59.05M | 98.82M | 96.70M | 16.97M | 0.33M |
| Change to operating activities | -1.73M | 1.75M | 1.52M | 1.22M | - |
| Net income | -56.80M | -93.04M | -33.94M | -18.34M | -0.91M |
| Change in cash | 8.60M | 53.45M | 73.39M | 11.49M | 0.16M |
| Begin period cash flow | 133.54M | 80.09M | 6.70M | - | - |
| End period cash flow | 142.14M | 133.54M | 80.09M | 6.70M | - |
| Total cash from operating activities | -50.14M | -45.82M | -23.60M | -5.48M | -0.77M |
| Issuance of capital stock | 42.30M | 81.92M | 71.99M | - | - |
| Depreciation | 3.18M | 2.62M | 0.55M | 0.02M | 0.01M |
| Other cashflows from investing activities | - | -0.30M | - | 0.11M | 1.68M |
| Change to account receivables | - | - | -0.01M | -0.01M | - |
| Sale purchase of stock | 60.96M | 98.82M | 97.38M | 0.32M | 0.35M |
| Other cashflows from financing activities | 16.75M | 16.90M | 24.71M | -0.40M | - |
| Change to netincome | 5.72M | 41.56M | 8.28M | 9.55M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.34M | 1.11M |
| Cash flows other operating | 0.23M | -2.88M | - | - | - |
| Cash and cash equivalents changes | 8.91M | 52.70M | - | - | - |
| Change in working capital | -3.78M | 1.88M | 2.06M | 0.23M | -0.02M |
| Stock based compensation | 13.71M | 42.72M | 7.41M | - | - |
| Other non cash items | -6.45M | 1.16M | 0.87M | - | - |
| Free cash flow | -50.14M | -45.82M | -23.60M | - | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.64 1.57% |
40.06 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.09 1.51% |
542.29 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.85 0.30% |
960.62 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert Barrow | CEO & Director | 1989 |
| Dr. Miriam Halperin Wernli Ph.D. | Exec. Pres | 1953 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 1980 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 1957 |
| Mr. Leonard Latchman | Co-founder | NA |
| Mr. Schond L. Greenway | Chief Financial Officer | 1972 |
| Ms. Carrie F. Liao CPA, CGMA | VP, Corp. Controller & Accounting Principal | NA |
| Ms. Wong Hu J.D. | Chief Legal Officer & Corp. Sec. | 1970 |
| Dr. Francois P. Lilienthal M.B.A., M.D. | Chief Commercial Officer | NA |
| Mr. Schond L. Greenway M.B.A. | Chief Financial Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.